Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Center for Immuno-Oncology Studies

Plain-language summary

This is a follow-up protocol providing long-term monitoring for people who previously took part in a gene therapy study at the NCI Center for Immuno-Oncology. It enrolls, by invitation, people aged 18 and older who were enrolled in an applicable NCI gene therapy treatment protocol. It is a study without an assigned phase and enrolls by invitation.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Enrolling by invitation

Sponsor

National Cancer Institute (NCI)

Intervention

GeneTherapy

Start date

5/8/2020

Estimated completion

10/1/2050

Countries

United States

Related genes

Locations

• Bethesda, United States

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

* INCLUSION CRITERIA:
* Subjects who have enrolled on an applicable NCI CIO gene therapy treatment protocol. Age \>= 18 years. Note: Children are generally excluded from CIO gene therapy studies and inclusion on this follow-up study will be limited to 18 years and older.

EXCLUSION CRITERIA:

-Children